Allogene Therapeutics, Inc. Operating Lease, Lease Income
Allogene Therapeutics, Inc. (ALLO) reported Operating Lease, Lease Income of $700.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseLeaseIncome · last filed 2026-08-12
- Allogene Therapeutics, Inc. operating lease, lease income for the quarter ending 2026-06-30 was $700.00K, a 12.50% decline year-over-year.
- Allogene Therapeutics, Inc. operating lease, lease income for the quarter ending 2026-03-31 was $800.00K, a 166.67% increase year-over-year.
- Allogene Therapeutics, Inc. operating lease, lease income for the quarter ending 2025-12-31 was $700.00K.
- Allogene Therapeutics, Inc. operating lease, lease income for the quarter ending 2025-09-30 was $700.00K.
- Allogene Therapeutics, Inc. operating lease, lease income for fiscal 2025 was $2.60M, a 2500.00% increase from fiscal 2024.
- Allogene Therapeutics, Inc. operating lease, lease income for fiscal 2024 was $100.00K.
| Period end | Operating Lease, Lease Income 3 month | Operating Lease, Lease Income 6 month | Operating Lease, Lease Income 9 month | Operating Lease, Lease Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $700.00K 10-Q · filed 2026-08-12 | $1.50M 10-Q · filed 2026-08-12 | $2.20M derived: sum of 3 quarters · filed 2026-08-12 | $2.90M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $800.00K 10-Q · filed 2026-05-13 | $1.50M derived: sum of 2 quarters · filed 2026-05-13 | $2.20M derived: sum of 3 quarters · filed 2026-05-13 | $3.00M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.40M derived: sum of 2 quarters · filed 2026-03-12 | $2.20M derived: sum of 3 quarters · filed 2026-08-12 | $2.60M 10-K · filed 2026-03-12 |
| 2025-09-30 | $700.00K 10-Q · filed 2025-11-06 | $1.50M derived: sum of 2 quarters · filed 2026-08-12 | $1.90M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $800.00K 10-Q · filed 2026-08-12 | $1.20M 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $100.00K 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |